October 23–27, 2026 · Madrid · 3101 items
54 people · 72 posts · 2 abstracts
Heat now 27·Peak in the comparable set 30 (Oct 25 03:00)·Change over 24h in the comparable set –·Participants now 37
Adjuvant pembrolizumab is already a standard after resection of stage IIB–IV melanoma. KEYNOTE-942 was a randomised phase 2b of individualised neoantigen mRNA (then mRNA-4157 / V940) plus pembrolizumab versus pembrolizumab alone; Lancet 2024 reported recurrence-free survival, not overall survival.[1] A 2026 JCO paper updates that trial at five years.[2] Those are phase-2 numbers, not this phase 3.
INTerpath-001 (NCT05933577) is the phase-3 follow-on, not the same trial: intismeran autogene plus pembrolizumab versus pembrolizumab alone. Floor LBA1 (Presidential I) reports n=1137, RFS hazard ratio 0.58, 2-year RFS 82.2% vs 70.0%; distant metastasis-free survival also met; OS immature. Floor copy says no new safety signals. Full confidence intervals, stage and BRAF strata wait on the slides.
What this adds to 942 is the same combination in 1137 patients, with both RFS and DMFS met. OS is immature; an RFS hazard ratio of 0.58 is not yet a rewrite of adjuvant melanoma care. Manufacturing turnaround and access for individualised mRNA are not in the floor posts. Keep the meeting numbers separate from the 942 papers.
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.orgA milestone for personalized cancer vaccines.
A question for the INTerpath-001 panel:
Ahead of #ESMO26, #CancerVaccines are generating global attention, but what questions still need answering before they can reshape #ClinicalPractice? Read more in an interview with James Larkin, ESMO Congress 2026 Scientific Co-Chair 🔗 https://ow.ly/Hzug50ZXEg9 #InsightsbyESMO
At ESMO 2026, the intismeran INTerpath-001 results showed a 42% reduction in melanoma recurrence risk and a 38% reduction in the risk related to distant metastasis-free survival. In the same session, in DeLLphi-305, 563 patients with extensive-stage small cell lung cancer received Imdelltra plus Imfinzi, with a 58% reduction in the risk of death; median overall survival was slightly above 21 months versus under 13 months with Imfinzi alone. Nearly half experienced cytokine release syndrome, mostly mild to moderate.
Why it matters: The original article compares intismeran with neoadjuvant immunotherapy and adds discussion of overall survival, mechanism of benefit, and barriers to mRNA adoption.
Clinical results for mRNA cancer vaccines are diverging. The Phase 3 INTerpath-001 trial read out positive, while BNT113 combined with pembrolizumab failed to significantly improve PFS in first-line treatment.
Detailed INTerpath-001 data appear to have leaked ahead of ESMO 2026, raising efficacy questions and sending Moderna shares sharply lower. According to the original report, after a median follow-up of 24.6 months, adding intismeran to pembrolizumab reduced the risk of recurrence or death, HR = 0.58. At 2 years, 82.2% of patients on the combination were alive and recurrence-free versus 70.0% on pembrolizumab alone.
Why it matters: The brief lists INTerpath-001's HR and 2-year recurrence-free survival comparison, giving context for efficacy questions raised by the suspected leak.
Phase 3 INTerpath-001 melanoma data leaked accidentally ahead of ESMO 2026. Intismeran autogene combined with Keytruda met the primary endpoint, with an RFS hazard ratio of 0.58, corresponding to a 42% reduction in the risk of recurrence or death.